1. Yang L, Fang A, Zhou S, Liu H. -RAMP3 promotes hepatocellular carcinoma tumor cell-mediated CCL2 degradation by supporting membrane distribution of ACKR2. Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113419. doi: 10.1016/j.intimp.2024.113419. Epub 2024 Oct 21. PMID: 39437486.
2. Hou Y, Sun L, LaFleur MW, Huang L, Lambden C, Thakore PI, Geiger-Schuller K, Kimura K, Yan L, Zang Y, Tang R, Shi J, Barilla R, Deng L, Subramanian A, Wallrapp A, Choi HS, Kye YC, Ashenberg O, Schiebinger G, Doench JG, Chiu IM, Regev A, Sharpe AH, Kuchroo VK. Neuropeptide signalling orchestrates T cell differentiation. Nature. 2024 Nov;635(8038):444-452. doi: 10.1038/s41586-024-08049-w. Epub 2024 Oct 16. PMID: 39415015; PMCID: PMC11951087.
3.Yan H, Xing Z, Liu S, Gao P, Wang Q, Guo G. CALCR exacerbates renal cell carcinoma progression via stabilizing CD44. Aging (Albany NY). 2024 Jul 9;16(13):10765-10783. doi: 10.18632/aging.205586. Epub 2024 Jul 9. PMID: 38985127; PMCID: PMC11272109.
4.He T, Ling F. CALCR knockdown inhibits the development and progression of non-small-cell lung cancer. Carcinogenesis. 2021 Nov 12;42(11):1390-1398. doi: 10.1093/carcin/bgab076. PMID: 34417812.